logo

Bicycle Therapeutics (BCYC)



Trade BCYC now with
  Date
  Headline
11/8/2022 7:08:44 AM Bicycle Therapeutics Announces First Patient Dosed In BT8009 Phase II Expansion Cohorts
11/3/2022 7:20:37 AM Bicycle Therapeutics Q3 Net Loss $28.3 Mln Or $0.96/shr Vs Net Loss $14.7 Mln Or $0.59/shr Priro Year
9/7/2022 7:10:33 AM Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results In Patients With Advanced Solid Tumors
8/4/2022 7:29:49 AM Bicycle Therapeutics Q2 Net Loss Widens To $26.8 Mln From $17.9 Mln Last Year
7/12/2022 7:11:11 AM Genentech Expands Strategic Collaboration Agreement With Bicycle To Develop Bicycle-based Immuno-oncology Therapies
6/8/2022 7:12:45 AM Bicycle Therapeutics Doses First Patient In Expansion Cohorts Of Phase I/II Trial Of Bicycle Toxin Conjugate BT5528
5/5/2022 7:16:30 AM Bicycle Therapeutics Q1 Net Loss $27.6 Mln Or $0.93/shr Vs Net Loss Of $16.2 Mln Or $0.73/shr Prior Year
4/11/2022 7:04:17 AM Bicycle Therapeutics Presents Interim BT8009 Phase I Clinical Trial Results At 2022 AACR Annual Meeting
4/7/2022 8:05:20 AM BCYC : Preclinical Results Provides Evidence For Bicycles As Potential Novel Antiviral Modality Against SARS-CoV-2
1/5/2022 7:05:52 AM Bicycle Therapeutics Announces Continued Progress In Phase I/II Trials Of BT8009, BT5528 And BT7480
11/4/2021 7:15:04 AM Bicycle Therapeutics Q3 Net Loss Widens To $14.7 Mln From $10.1 Mln Last Year
11/2/2021 7:15:31 AM Bicycle Announces Publication Of Article Highlighting Preclinical Data From BT7480 Program On ImmunoTherapy Of Cancer
10/26/2021 7:16:12 AM Bicycle Therapeutics Announces Expansion Of Genentech Immuno-Oncology Collaboration
10/13/2021 12:40:15 AM Bicycle Therapeutics Announces Pricing Of Upsized Public Offering Of 3.24 Mln ADSs At $54/ADS
10/12/2021 7:09:56 AM Bicycle Therapeutics Announces Proposed $125 Mln Public Offering Of ADSs
8/5/2021 7:21:30 AM Bicycle Therapeutics Q2 Net Loss $17.9 Mln Vs Net Loss $12.1 Mln Last Year
7/13/2021 7:10:08 AM Ionis Pharma Enters Deal With Bicycle Therapeutics To Increase Delivery Capabilities Of Ionis' Advanced LICA Medicines